Cipla Limited had to tackle some pre-results drama, even as the company reported a strong showing for the third quarter of fiscal 2024, while management commentary on the glucagon‐like peptide 1 (GLP-1) receptor agonist segment signaled huge potential opportunities in store.
Samina Hamied Moves To Non-Executive Role
Cipla’s executive vice chairperson and member of the founding family, Samina Hamied, will be stepping down from her current position “due to personal and family commitments”. The move is effective close of business hours of 31 March, though Ms Hamied will continue to be a non-executive director liable to retire by rotation at the Mumbai-based company.
The executive, who is the daughter of vice chairman M K Hamied, and niece of chair Dr Yussuf K Hamied, who are both in their eighties, noted that a decade ago the senior founding family members believed that Cipla needed an “engaged and active promoter” from the next generation to steer and strengthen the company as it built a world class leadership team, forayed into new geographies and incubated new businesses.
“Today as I step down from my executive position, I am proud to say that Cipla is strong and resilient and ready for the future,” Ms Hamied stated.
Cipla’s CEO and MD Umang Vohra said that the role switch was driven more with the overall promoter family plan to “create an institution for Cipla that survives various promoter transitions”.
‘As much as they are planning for it, I have to also plan for the management continuity of this company so that the company stays professional and has an ever-growing and everlasting phenomenon to it,” Vohra said in response to an analysts question on the earnings call.
Ms Hamied’s role change comes amid speculation over the past of a potential sale of the company which was established in 1935 and whose journey is steeped in history and with many firsts. In 2001 Cipla had famously introduced the first once-daily triple cocktail for HIV/AIDS at a cost of less than a dollar a day, transforming the treatment landscape and expanding access to those critical drugs manifold in Africa and elsewhere.
CEO Vohra, though, maintained there hasn’t been “any discussion or any information or any dialogue over the last at least two to three months that we are aware of” on the potential sale.(Also see "
There was also an important results-day announcement – Cipla’s executive vice chairperson and member of the founding family, Samina Hamied, stepped down from the position,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
